Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1821. Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan

Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan Okubo I, Kondo M, Toi M, Ochiai T, Miki S Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of letrozole and tamoxifen as first-line hormonal treatments in advanced breast cancer were compared. Type of intervention Treatment. Economic study type Cost-effectiveness analysis

NHS Economic Evaluation Database.2005

1822. Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective

Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective Is adjuvant therapy for older patients with node (-) early breast cancer cost-effective Naeim A, Keeler E B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The present study compared five treatment options for node negative (-) breast cancer in elderly women: cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) x6 chemotherapy; adriamycin, cyclophosphamide (AC) x4 chemotherapy; tamoxifen hormone therapy (HRT) x5 years; tamoxifen HRT+CMF; and tamoxifen HRT+AC. All strategies were compared with the reference strategy of giving no adjuvant therapy

NHS Economic Evaluation Database.2005

1823. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective?

Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it cost-effective? Norum J, Holtmon M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of adjuvant chemotherapy (ACT) based on cyclophosphamide, epirubicin and fluorouracil (FEC) for the treatment of early breast cancer (BC). Fluorouracil and cyclophosphamide were given at a dose of 600 mg/m2 every 3 weeks, while epirubicin was given at a dose of 60 mg/m2 every 3 weeks. Type of intervention Treatment. Economic study type Cost

NHS Economic Evaluation Database.2005

1824. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Oestreicher N, Ramsey S D, Linden H M, McCune J S, Van't Veer L J, Burke W, Veenstra D L Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of gene expression profiling (GEP) among premenopausal women newly diagnosed with Stage I or II breast cancer, to target adjuvant chemotherapy for those at high risk of distant recurrence, was examined. The study focused on the Netherlands Cancer Institute GEP

NHS Economic Evaluation Database.2005

1825. Aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor-positive early breast cancer

Aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor-positive early breast cancer Cancer Australia | A national government agency working to reduce the impact of cancer on all Australians ") //--> ") //--> Search form Search News Featured Sites Featured Video Visit our channel Video of Introduction to the Statement View the video transcript ( ) Cancer types A - Z list of cancer types In Focus Copyright © 2017 - Cancer Australia

National Breast and Ovarian Cancer Centre2005

1826. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations

A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations Shen Y, Parmigiani G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated a total of 48 screening strategies for breast cancer. Each strategy was determined by the combination of an age range (40 - 79, 45 - 79 and 50 - 79 years), an interval between examinations (0.5, 1, 1.5 and 2 years), and whether mammography and clinical breast examination (CBE) were given at every exam or at every

NHS Economic Evaluation Database.2005

1827. Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer

Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer Cost-effectiveness of new guidelines for adjuvant systemic therapy for patients with primary breast cancer Kievit W, Bolster M J, van der Wilt G J, Bult P, Thunnissen F B, Meijer J, Strobbe L J, Klinkenbijl J H, Wobbes T, Adang E M, Beex L V, Tjan Heijnen V C Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined guidelines for the use of adjuvant systemic therapy for patients with primary breast cancer (BC). Adjuvant systemic therapy could consist of chemotherapy and/or endocrine therapy. Endocrine

NHS Economic Evaluation Database.2005

1828. Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer

Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer Economic consequence of local control with radiotherapy: cost analysis of internal mammary and medial supraclavicular lymph node radiotherapy in breast cancer Lievens Y, Kesteloot K (...) , van den Bogaert W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of internal mammary and medial supraclavicular lymph node region radiotherapy (IM-MS RT) after surgery for Stage I-III breast cancer

NHS Economic Evaluation Database.2005

1829. A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer

A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer A cost-effectiveness analysis of two rehabilitation support services for women with breast cancer Gordon L G, Scuffham P, Battistutta D, Graves N, Tweeddale M, Newman B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two rehabilitation interventions for breast cancer survivors. The first intervention, Domiciliary Allied Health and Acute Care Rehabilitation Team (DAART), was described as an early, home-based physiotherapy intervention. The second intervention, Strength Through Recreation Exercise Togetherness

NHS Economic Evaluation Database.2005

1831. Manual lymph drainage combined with compression therapy for arm lymphedema following breast cancer treatment - early assessment briefs (Alert)

Manual lymph drainage combined with compression therapy for arm lymphedema following breast cancer treatment - early assessment briefs (Alert) Manual lymph drainage combined with compression therapy for arm lymphedema following breast cancer treatment - early assessment briefs (Alert) Manual lymph drainage combined with compression therapy for arm lymphedema following breast cancer treatment - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Swedish Council on Technology Assessment in Health Care. Manual lymph drainage combined with compression therapy for arm lymphedema following breast cancer treatment - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2005 Authors' objectives This review aims to assess

Health Technology Assessment (HTA) Database.2005

1832. Aromatase inhibitors in breast cancer - early assessment briefs (Alert)

Aromatase inhibitors in breast cancer - early assessment briefs (Alert) Aromatase inhibitors in breast cancer - early assessment briefs (Alert) Aromatase inhibitors in breast cancer - early assessment briefs (Alert) Swedish Council on Technology Assessment in Health Care Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Swedish Council (...) on Technology Assessment in Health Care. Aromatase inhibitors in breast cancer - early assessment briefs (Alert) Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 2005 Authors' objectives This review aims to assess the extent to which aromatase inhibitors are more effective than anti-estrogen drugs in adjuvant treatment of breast cancer and as first-line therapy for advanced breast cancer in postmenopausal women. Authors' conclusions In advanced disease, aromatase inhibitors as first

Health Technology Assessment (HTA) Database.2005

1833. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions

Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions Wilson B J, Torrance N, Mollison J, Wordsworth S, Gray J R (...) , Haites N E, et al Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wilson B J, Torrance N, Mollison J, Wordsworth S, Gray J R, Haites N E, et al. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions. Health Technology Assessment 2005; 9(3): 1-166

Health Technology Assessment (HTA) Database.2005

1834. Gene expression profiling for managing breast cancer treatment

Gene expression profiling for managing breast cancer treatment Gene expression profiling for managing breast cancer treatment Gene expression profiling for managing breast cancer treatment BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent (...) 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Gene expression profiling for managing breast cancer treatment. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 20(3). 2005 Authors' objectives The objective of this Assessment is to review the available evidence on the use of panels of gene expression markers that appear to predict the likelihood of breast cancer recurrence

Health Technology Assessment (HTA) Database.2005

1835. Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review

Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review Trastuzumab as adjuvant therapy for early stage breast cancer - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Trastuzumab (...) as adjuvant therapy for early stage breast cancer - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to assess the potential for future impact of Trastuzumab as adjuvant therapy for early stage breast cancer. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Breast Neoplasms /drug therapy Language Published English Country of organisation

Health Technology Assessment (HTA) Database.2005

1836. Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review

Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review Temsirolimus for locally advanced and metastatic breast cancer - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Temsirolimus (...) for locally advanced and metastatic breast cancer - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 Authors' objectives This study aims to assess the potential for future impact of temsirolimus for locally advanced and metastatic breast cancer Authors' conclusions Temsirolimus (CCI-779) inhibits the protein mTOR kinase and prevents cell division and tumour growth. It is currently in phase III clinical trials in combination with letrozole for the first-line treatment

Health Technology Assessment (HTA) Database.2005

1839. The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-Overexpressing Metastatic Breast Cancer

The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-Overexpressing Metastatic Breast Cancer

Cancer Care Ontario2005